LJPC - La Jolla Pharmaceutical Company
| Previous Close | 13.81 |
| Open | 14.03 |
| Bid | 12.00 x 1000 |
| Ask | 18.75 x 1800 |
| Day's Range | 13.38 - 14.08 |
| 52 Week Range | 12.86 - 41.36 |
| Volume | 271,006 |
| Avg. Volume | 407,371 |
| Market Cap | 367.27M |
| Beta (3Y Monthly) | 3.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.92 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.17 |
- Thomson Reuters StreetEvents•last month
Edited Transcript of LJPC earnings conference call or presentation 24-Oct-18 8:30pm GMT
Q3 2018 La Jolla Pharmaceutical Co Earnings Call
- ACCESSWIRE•2 months ago
3 Healthcare Stocks To Watch On Thursday
CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.
- Zacks•2 months ago
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
La Jolla Pharmaceutical: 3Q Earnings Snapshot
The San Diego-based company said it had a loss of $1.93 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018
SAN DIEGO, Oct. 24, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Benzinga•2 months ago
The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 23) Amarin Corporation plc (NASDAQ: AMRN ) Imprimis Pharmaceuticals ...
- GlobeNewswire•2 months ago
La Jolla Pharmaceutical Company to Release Third Quarter 2018 Financial Results on October 24, 2018
SAN DIEGO, Oct. 18, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Simply Wall St.•2 months ago
Why You Need To Look At This Factor Before Buying La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Anyone researching La Jolla Pharmaceutical Company (NASDAQ:LJPC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
- GlobeNewswire•2 months ago
Recent Analysis Shows Professional Diversity Network, Quanex Building Products, HTG Molecular Diagnostics, La Jolla Pharmaceutical, Playa Hotels & Resorts N.V, and Plexus Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of LJPC earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 La Jolla Pharmaceutical Co Earnings Call
- Motley Fool•4 months ago
Why La Jolla Pharmaceutical Is Tumbling Today
Shares drop off after the company reports second-quarter results that left investors wanting more.
- Zacks•4 months ago
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
La Jolla Pharmaceutical: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
- ACCESSWIRE•4 months ago
La Jolla Pharmaceutical Company to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
- ACCESSWIRE•5 months ago
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- InvestorPlace•6 months ago
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
- ACCESSWIRE•6 months ago
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
